Publications by authors named "David A Cameron"

Claim this Profile
P
Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients.
Matteo Lambertini, Deirdre Allegranza, Ruediger P Laubender, Nadia Harbeck, Sandra M Swain, David A Cameron

J Natl Cancer Inst· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to Li, Liu, Duan, et al.
Per Karlsson, Anthony Fyles, Bradley Arrick, Erik Holmberg, Martin Sjöström, David A Cameron

J Natl Cancer Inst· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hidden costs and unmet supportive care needs among individuals with experience of breast cancer and their carers in the United Kingdom.
Szeyi Ng, Lucy S Kilburn, Hilary Stobart, Lesley Stephen, Indrani S Bhattacharya, David A Cameron

BJC Rep· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced duration adjuvant trastuzumab in the treatment of patients with HER2-positive breast cancer: a meta-analysis of randomised controlled non-inferiority trials including IPD data.
Helena M Earl, Louise Hiller, Janet A Dunn, Mubarak Patel, PierFranco Conte, David A Cameron

BMJ Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBC.
Naoto T Ueno, Francesco Cottone, Kyle Dunton, William Jacot, Toshinari Yamashita, David A Cameron

Oncologist· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of a breast cancer assay for radiotherapy omission: an individual participant data meta-analysis.
Per Karlsson, Anthony Fyles, S Laura Chang, Bradley Arrick, Frederick L Baehner, David A Cameron

J Natl Cancer Inst· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): a multicentre, randomised, phase 3, non-inferiority trial.
Janet A Dunn, Peter Donnelly, Nada Elbeltagi, Andrea Marshall, Amy Hopkins, David A Cameron

Lancet· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical Trial.
Michail Ignatiadis, Andrew Bailey, Heather McArthur, Sarra El-Abed, Evandro de Azambuja, David A Cameron

JAMA· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emergency and non-emergency routes to cancer diagnoses in 2020 and 2021: A Population-based study of 154,863 patients.
Calum Purdie, Gavin R C Clark, David A Cameron, Russell Petty, Paramananthan Mariappan

J Cancer Policy· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Profile analysis in listeners with normal and elevated audiometric thresholds: Behavioral and modeling results.
Daniel R Guest, David A Cameron, Douglas M Schwarz, U-Cheng Leong, Virginia M Richards

J Acoust Soc Am· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Postoperative radiotherapy in women with early operable breast cancer (Scottish Breast Conservation Trial): 30-year update of a randomised, controlled, phase 3 trial.
Linda J Williams, Ian H Kunkler, Karen J Taylor, Joanna Dunlop, Tammy Piper, David A Cameron

Lancet Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Lancet Breast Cancer Commission.
Charlotte E Coles, Helena Earl, Benjamin O Anderson, Carlos H Barrios, Maya Bienz, David A Cameron

Lancet· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intrinsic Subtype and Overall Survival of Patients with Advanced HR+/HER2- Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7.
Aleix Prat, Nadia Solovieff, Fabrice André, Joyce O'Shaughnessy, David A Cameron

Clin Cancer Res· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thromboxane biosynthesis in cancer patients and its inhibition by aspirin: a sub-study of the Add-Aspirin trial.
Nalinie Joharatnam-Hogan, Duaa Hatem, Fay H Cafferty, Giovanna Petrucci, David A Cameron

Br J Cancer· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of sensorineural hearing loss on formant-frequency discrimination: Measurements and models.
Laurel H Carney, David A Cameron, Kameron B Kinast, C Evelyn Feld, Douglas M Schwarz

Hear Res· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study.
Ailsa J Oswald, Stefan N Symeonides, Duncan Wheatley, Stephen Chan, Adrian Murray Brunt, David A Cameron

Breast Cancer Res Treat· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EBCC-13 manifesto: Balancing pros and cons for contralateral prophylactic mastectomy.
Marjanka K Schmidt, Jennifer E Kelly, Anne Brédart, David A Cameron, Jana de Boniface

Eur J Cancer· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Scottish COVID Cancer Immunity Prevalence Study: A Longitudinal Study of SARS-CoV-2 Immune Response in Patients Receiving Anti-Cancer Treatment.
Karin Purshouse, John P Thomson, Mahéva Vallet, Lorna Alexander, Isaac Bonisteel, David A Cameron

Oncologist· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breast-Conserving Surgery with or without Irradiation in Early Breast Cancer.
Ian H Kunkler, Linda J Williams, Wilma J L Jack, David A Cameron, J Michael Dixon

N Engl J Med· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer.
Matteo Lambertini, Marcello Ceppi, Richard A Anderson, David A Cameron, Marco Bruzzone

J Natl Compr Canc Netw· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reproductive history differs by molecular subtypes of breast cancer among women aged ≤ 50 years in Scotland diagnosed 2009-2016: a cross-sectional study.
Anushri Chitkara, Ines Mesa-Eguiagaray, Sarah H Wild, Peter S Hall, David A Cameron

Breast Cancer Res Treat· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Shanu Modi, William Jacot, Toshinari Yamashita, Joohyuk Sohn, Maria Vidal, David A Cameron

N Engl J Med· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results.
Nigel Bundred, Nuria Porta, Adrian Murray Brunt, Angela Cramer, Andrew Hanby, David A Cameron

Clin Cancer Res· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.
Gabriel N Hortobagyi, Salomon M Stemmer, Howard A Burris, Yoon-Sim Yap, Gabe S Sonke, David A Cameron

N Engl J Med· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Collateral-resistance to estrogen and HER-activated growth is associated with modified AKT, ERα, and cell-cycle signaling in a breast cancer model.
Kate M Moore, Vera Cerqueira, Kenneth G MacLeod, Peter Mullen, Richard L Hayward, David A Cameron

Explor Target Antitumor Ther· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis